CTMX.US CytomX Therapeutics Inc

Healthcare Biotechnology USA Stocks
2.04 USD
Close of Nov 14, 2026
1.90 8.21
Market cap
USD 445M
P/E
-
P/B
1.56x
ROE
-27.6%
Dividend yield
0.68%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CTMX.US undervalued?

Graham number

The Graham number of CytomX Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CytomX Therapeutics Inc fundamental analysis

No fundamental analysis for CytomX Therapeutics Inc yet.

CytomX Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index fo…

Full company profile